Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Chief Scientific Officer | July 21, 2026 | July 23, 2026 |
| EQRx, Inc.CMLT · Entity 108311 | Director | April 06, 2021 | April 06, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date July 21, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 812,058 |
Ending reported balance
After 2026-07-21 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-07-21 · Exercise / conversion · Acquired 284,800 · Balance 1,304,458 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. Row 2 · 2026-07-21 · Sale · Disposed 278,698 · Balance 1,025,760 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.90 to $21.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 3 · 2026-07-21 · Sale · Disposed 213,702 · Balance 812,058 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.90 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.55 · Expires 2028-02-07 | Direct | 0 |
Reported balance
After 2026-07-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-21 · Exercise / conversion · Disposed 284,800 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F4: The option was fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.90 to $21.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.90 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4: The option was fully vested and exercisable.
EQRx, Inc.
Report date April 06, 2021 · Filed April 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-04-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-253475) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-253475) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2026 Filed Jul 23, 2026 23:34 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 284,800 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780851-26-000017 · form4.xml · derivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 284,800 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F4 · derivative.exercise_date: The option was fully vested and exercisable. Read SEC document |
| July 21, 2026 Filed Jul 23, 2026 23:34 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 213,702 | $22.12 | $4,727,088.24 |
DisclosureSEC source: 0001780851-26-000017 · form4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 812,058 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.90 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 21, 2026 Filed Jul 23, 2026 23:34 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 278,698 | $21.72 | $6,053,320.56 |
DisclosureSEC source: 0001780851-26-000017 · form4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,025,760 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.90 to $21.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 21, 2026 Filed Jul 23, 2026 23:34 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 284,800 | $6.55 | $1,865,440.00 |
DisclosureSEC source: 0001780851-26-000017 · form4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,304,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 22:52 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 146,889 | $22.45 | $3,297,658.05 |
DisclosureSEC source: 0001780851-26-000015 · form4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,019,658 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $22.15 to $22.75, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 22:52 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 239,351 | $21.74 | $5,203,490.74 |
DisclosureSEC source: 0001780851-26-000015 · form4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,166,547 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.15 to $22.145, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 00:11 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 6,160 | $18.01 | $110,941.60 |
DisclosureSEC source: 0001780851-26-000013 · form4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,405,898 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $18.00 to $18.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:11 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 100,000 | $17.37 | $1,737,000.00 |
DisclosureSEC source: 0001780851-26-000013 · form4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,412,058 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $17.14 to $17.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 22:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,000 | $14.85 | $148,500.00 |
DisclosureSEC source: 0001780851-26-000011 · form4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,512,058 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $14.65 to $15.06, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 00:49 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 329,600 | $13.17 | $4,340,832.00 |
DisclosureSEC source: 0001780851-26-000007 · form4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,522,058 F2 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance share units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 00:49 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 140,666 | $13.17 | $1,852,571.22 |
DisclosureSEC source: 0001780851-26-000007 · form4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,851,658 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 06, 2026 Filed Mar 7, 2026 00:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 709,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001780851-26-000005 · form4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,992,324 F1 · kind: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. The performance share units were granted on March 6, 2023, with respect to the three-year period ending on March 6, 2026. The issuer certified the achievement of the performance goals on March 6, 2026. The performance share units vested on March 6, 2026. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 00:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 127,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001780851-26-000005 · form4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,283,104 Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 00:58 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 14,233 | $16.52 | $235,129.16 |
DisclosureSEC source: 0001780851-26-000003 · primary_doc.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,155,291 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:58 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,000 | $15.72 | $157,200.00 |
DisclosureSEC source: 0001780851-26-000003 · primary_doc.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,169,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.57 to $15.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 00:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 8,120 | $19.00 | $154,280.00 |
DisclosureSEC source: 0001780851-26-000002 · primary_doc.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,179,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.56 to $19.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 00:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 34,668 | $18.60 | $644,824.80 |
DisclosureSEC source: 0001780851-26-000002 · primary_doc.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,187,644 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.26 to $18.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 06, 2026 Filed Jan 9, 2026 01:17 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,000 | $16.44 | $164,400.00 |
DisclosureSEC source: 0001780851-26-000001 · primary_doc.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,222,312 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.78, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:30 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,000 | $16.61 | $166,100.00 |
DisclosureSEC source: 0001780851-25-000003 · primary_doc.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,232,312 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading plan adopted by the reporting person on August 11, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.45 to $16.95, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 23:30 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 27,212 | $18.61 | $506,415.32 |
DisclosureSEC source: 0001780851-25-000003 · primary_doc.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,242,312 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading plan adopted by the reporting person on August 11, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.50 to $18.71, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 00:30 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,000 | $14.82 | $148,200.00 |
DisclosureSEC source: 0001780851-25-000002 · primary_doc.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,269,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.58 to $15.05, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:27 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 68,412 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001062993-25-008509 · form4.xml · derivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 68,412 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025. F3 · derivative.exercise_date: The option was fully vested and exercisable. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:27 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 68,412 | $7.35 | $502,828.20 |
DisclosureSEC source: 0001062993-25-008509 · form4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,279,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.18 to 7.51, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:27 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 68,412 | $6.32 | $432,363.84 |
DisclosureSEC source: 0001062993-25-008509 · form4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,347,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 22:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,698 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001062993-25-006335 · form4.xml · derivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,412 Underlying: Common Stock · 1,698 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 22:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,698 | $9.00 | $15,282.00 |
DisclosureSEC source: 0001062993-25-006335 · form4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,279,524 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $9.00 to 9.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 22:48 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 1,698 | $6.32 | $10,731.36 |
DisclosureSEC source: 0001062993-25-006335 · form4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,281,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:18 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 56,053 | $6.99 | $391,810.47 |
DisclosureSEC source: 0001062993-25-004810 · form4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,279,524 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:18 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 40,603 | $6.98 | $283,408.94 |
DisclosureSEC source: 0001062993-25-004810 · form4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,335,577 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:18 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 355,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-004810 · form4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,376,180 Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 354,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-005760 · form4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,021,180 Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 354,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-006322 · form4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,570 Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 4,517 | $12.01 | $54,249.17 |
DisclosureSEC source: 0001209191-22-017394 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,960 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 617,792 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-017394 · doc4.xml · derivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 617,792 Underlying: Common Stock · 617,792 shares Expires 2032-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 247,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017394 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,477 Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:59 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-065839 · doc4.xml · derivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,800 Underlying: Common Stock · 300 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:59 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 300 | $31.36 | $9,408.00 |
DisclosureSEC source: 0001209191-21-065839 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.00 to 31.76, inclusive. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:59 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 300 | $6.55 | $1,965.00 |
DisclosureSEC source: 0001209191-21-065839 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:59 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,700 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-065839 · doc4.xml · derivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,100 Underlying: Common Stock · 3,700 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:59 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,700 | $32.05 | $118,585.00 |
DisclosureSEC source: 0001209191-21-065839 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.45 to 32.36, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:59 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 3,700 | $6.55 | $24,235.00 |
DisclosureSEC source: 0001209191-21-065839 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,700 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · derivative · entry 10 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,800 Underlying: Common Stock · 3,700 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,700 | $33.73 | $124,801.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · nonDerivative · entry 7 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.08 to 33.99, inclusive. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 3,700 | $6.55 | $24,235.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · nonDerivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,700 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · derivative · entry 9 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,500 Underlying: Common Stock · 3,700 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,700 | $33.71 | $124,727.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · nonDerivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.08 to 34.01, inclusive. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 3,700 | $6.55 | $24,235.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. Read SEC document |
| October 19, 2021 Filed Oct 22, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,800 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · derivative · entry 8 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,200 Underlying: Common Stock · 3,800 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 19, 2021 Filed Oct 22, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,500 | $33.76 | $118,160.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.53 to 34.00, inclusive. Read SEC document |
| October 19, 2021 Filed Oct 22, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 300 | $32.91 | $9,873.00 |
DisclosureSEC source: 0001209191-21-061319 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,860 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $32.80 to 32.99, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.